Waldenström macroglobulinemia treatment algorithm 2018.

about

Peripheral Nervous System Involvement in Lymphoproliferative Disorders

P2860

Q58775562-51217B19-79ED-4BB7-A638-ABE9CC8E13D1

P2860

Waldenström macroglobulinemia treatment algorithm 2018.

Item

http://www.wikidata.org/entity/Q55018872

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Waldenström macroglobulinemia treatment algorithm 2018.

@en

Waldenström macroglobulinemia treatment algorithm 2018.

@nl

type

Item

label

Waldenström macroglobulinemia treatment algorithm 2018.

@en

Waldenström macroglobulinemia treatment algorithm 2018.

@nl

prefLabel

Waldenström macroglobulinemia treatment algorithm 2018.

@en

Waldenström macroglobulinemia treatment algorithm 2018.

@nl

P1476

Waldenström macroglobulinemia treatment algorithm 2018.

@en

P275

Creative Commons Attribution

P2860

Hepatitis C virus as a systemic disease: reaching beyond the liver

Cold agglutinin disease

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

P2888

s41408-018-0076-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/S41408-018-0076-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Morie A Gertz

P5008

ScienceSource

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103640954

http://www.w3.org/2001/XMLSchema#string

P698

29712895

http://www.w3.org/2001/XMLSchema#string

P921

Waldenström's macroglobulinemia

P932

5928091

http://www.w3.org/2001/XMLSchema#string

Waldenström macroglobulinemia treatment algorithm 2018.

about

P2860

P2860

Waldenström macroglobulinemia treatment algorithm 2018.

description

name

type

label

prefLabel

P1433

P1476

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P6179

P698

P921

P932

P356

P1433

P1476

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P5008

P577

P6179

P698

P921

P932